Vifor builds in kidney disease with Sanifit, Inositec buysOn the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by Share XVifor builds in kidney disease with Sanifit, Inositec buyshttps://pharmaphorum.com/news/vifor-builds-in-kidney-disease-with-sanifit-inositec-buys/
Renal disease: the big pictureRenal diseases represent a formidable challenge on public health systems around the world. They are costly in terms Share XRenal disease: the big picturehttps://pharmaphorum.com/r-d/renal-disease-the-big-picture/
Spain’s Sanifit raises €72 million for rare disease drug trialSanifit has raised €72.2 million ($80.9m) in Spain’s largest private biotech fundraiser to finance phase 3 clinical development Share XSpain’s Sanifit raises €72 million for rare disease drug trialhttps://pharmaphorum.com/news/spains-sanifit-raises-e72-million-for-rare-disease-drug-trial/
Spain’s Sanifit chasing calcium disorder blockbusterSpanish biotech Sanifit is targeting calcification disorders, and says it could have a potential multi-billion dollar treatment in Share XSpain’s Sanifit chasing calcium disorder blockbusterhttps://pharmaphorum.com/news/spains-sanifit-chasing-calcium-disorder-blockbuster/
